Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 348 · FY2023 4,587 · FY2024 5,117 — 3-yr total 10,052
Georgian pharmaceutical retail / wholesale company. Limited public information available beyond the Reportal filing.
Group parent — controls 1 company · ownership
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| 46,831 | 56,012 | 56,900 | 67,022 | 70,572 | 75,696 | 86,433 | 116,622 | +13.9% | |
| 22,982 | 27,441 | 44,647 | 45,365 | 54,317 | 59,878 | 66,099 | 71,453 | +17.6% | |
| TOTAL ASSETS | 69,813 | 83,453 | 101,547 | 112,386 | 124,889 | 135,573 | 152,532 | 188,074 | +15.2% |
| 60,780 | 64,601 | 69,478 | 89,940 | 86,437 | 87,245 | 101,096 | 125,430 | +10.9% | |
| Total Non-Current Liabilities | 9,298 | 1,125 | 2,870 | 3,277 | 11,457 | 15,702 | 14,121 | 25,145 | +15.3% |
| TOTAL LIABILITIES | 70,078 | 65,726 | 72,348 | 93,216 | 97,894 | 102,947 | 115,217 | 150,575 | +11.5% |
| 265 | 17,728 | 29,199 | 19,170 | 26,995 | 32,627 | 37,315 | 37,499 | nmf | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||||||
| Total Debt | 9,603 | 11,778 | 17,374 | 20,194 | 25,260 | 23,402 | 25,075 | 33,699 | +19.6% |
| Cash & Equivalents | 2,258 | 3,152 | 1,359 | 1,310 | 5,032 | 2,993 | 4,741 | 6,673 | +16.7% |
| Net Debt | 7,345 | 8,626 | 16,016 | 18,883 | 20,228 | 20,408 | 20,334 | 27,026 | +20.5% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →